Please login to the form below

Not currently logged in
Email:
Password:

NKTR-102

This page shows the latest NKTR-102 news and features for those working in and with pharma, biotech and healthcare.

Nektar hit by breast cancer trial setback

Nektar hit by breast cancer trial setback

Nektar hit by breast cancer trial setback. NKTR-102 failed to meet phase III targets. ... The development is also particularly disappointing for Nektar as NKTR-102 was a wholly owned project.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics